Sage shares rise after postpartum depression drug meets main goal

(Reuters) - Sage Therapeutics on Thursday said its drug to treat moderate and severe postpartum depression succeeded in reducing symptoms in patients enrolled in two late-stage trials, sending its shares up 50 percent in pre-market trade.